Cogstate’s computerised battery of rapid, reliable, simple and sensitive tests measures the cognitive domains affected by schizophrenia: processing speed, attention, verbal and visual learning, working memory, visual motor function, executive function and social cognition.
Tests can be grouped to match the cognitive domains recommended by the MATRICS group, or smaller groups of tests can be assembled to measure more specific domains. For each test, the construct validity for cognitive impairment in schizophrenia, as well as the sensitivity to change in cognition in schizophrenia has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical populations and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.
The Detection test measures processing speed using a simple reaction time paradigm.
The Identification test measures attention using a choice reaction time paradigm.
One Card Learning Test
The One Card Learning test measures visual memory using a pattern separation paradigm.
One Back Test
The One Back test measures working memory using an n-back paradigm.
Two Back Test
The Two Back test measures working memory using an n-back paradigm.
International Shopping List Test
The International Shopping List Test measures verbal learning using a word list learning paradigm.
Social-Emotional Cognition Test
The Social-Emotional Cognition Test measures emotional recognition using an odd-man out paradigm.
Groton Maze Learning Test
The Groton Maze Learning Test measures executive function using a maze learning paradigm.
Length: Approx. 35 minutes
(if all tests in the battery are selected*)
Data Processing and Scoring: Automated
Application: Phase I-IV
Culture and Language Neutral: Yes
Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., Detore, N. R., Altshuler, L. L., … Nuechterlein, K. H. (2011). Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophrenia Research, 132(1), 35-41. doi: 10.1016/j.schres.2011.06.029
Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N. & Hosford, D. A., (2013) A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacology, 38, 968-975.
Pietrzak, R. H., Snyder, P. , J.Maruff, P. (2010) Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 25, 353-358.
Preskorn, S. H., Gawryl, M., Dgetluck, N., Palfreyman, M., Bauer, L. O., & Hilt, D. C. (2014). Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. Journal of Psychiatric Practice, 20(1), 12–24. doi:10.1097/01.pra.0000442935.15833.c5
Riedel, M., Schmitz, M., Kåre, P., Ferrannini, L., Franco, M. A., Alfano, V., & Dencker, E. (2015). Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance , sedation and patient satisfaction in patients with schizophrenia : A randomised , double-blind , crossover study ( eXtRa ). Schizophrenia Research. doi:10.1016/j.schres.2014.12.027